Trial record 1 of 1 for:    NCT01683188
Previous Study | Return to List | Next Study

HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma (PROCLIVITY 01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01683188
Recruitment Status : Terminated (A shift in the melanoma treatment landscape adversely affected accrual & to early closure.)
First Posted : September 11, 2012
Last Update Posted : February 5, 2015
Information provided by (Responsible Party):
Prometheus Laboratories

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : November 2014
  Actual Study Completion Date : November 2014